One of the most successful examples is that the combination of atezolizumab (PD-L1 inhibitor) and bevacizumab has been approved by US FDA as a first-line treatment for patients with unresectable HCC based on unprecedented results of the IMbrave150 trial (11–13). Here, CD274 is linked to hepatocellular carcinoma.